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Acute myocardial infarction (AMI) and the heart failure (HF) that often follows are the leading 
causes of death and disability in Europe and worldwide. As such, new treatment strategies are 
needed to protect the heart against acute ischemia/reperfusion injury (IRI) in order to preserve 
cardiac function and prevent adverse left ventricular remodeling and HF – a strategy termed 
“cardioprotection.” Despite intensive experimental and clinical research since the discovery of the 
remarkable cardioprotective effect of ischemic preconditioning more than 3 decades ago, there 
are currently no effective cardioprotective therapies in clinical practice. The challenge has been to 
successfully translate novel cardioprotective therapies discovered in experimental studies into the 
clinical setting for patient benefit. 
This EU-CARDIOPROTECTION COST Action CA16225 will address this challenge by setting up a 
pan-European research network of leading experts in experimental and clinical cardioprotection, 
to jointly develop innovative strategies for translating novel cardioprotective therapies into 
the clinical setting. This will be achieved through 4 main research objectives, each linked to the 
activities of a Working Group (WG): (1) WG1 New Targets: to use innovative strategies to discover 
novel targets for cardioprotection, given that many of the established cardioprotective targets 
have so far failed; (2) WG2 Combination Therapy: to investigate the effects of using combination 
therapy directed to multiple targets as an innovative cardioprotective strategy, given that single-
targeted approaches to cardioprotection have so far failed; (3) WG3 Confounders: to use more 
clinically relevant animal AMI/HF models for testing novel cardioprotective therapies which take 
into account the confounding effects of co-morbidities and co-medications, given that many of 
the failed clinical studies have been based on therapies developed using juvenile healthy animal 
models; and (4) WG4 Consortium: to set up a European network of research centers (called the 
European Cardioprotection Consortium (ECC)) for multi-center randomized placebo-controlled 
testing of novel cardioprotective therapies in small/large animal AMI/HF models, and in AMI/HF 
patients, in order to improve the rigor of pre-clinical and clinical testing of novel cardioprotective 
therapies. In summary, the overall objective of the EU-CARDIOPROTECTION COST Action CA16225 
will be to improve the translation of novel cardioprotective therapies into the clinical setting for 
patient benefit.
*These two authors should be considered joint last authors.
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Acute myocardial infarction (AMI) and the heart failure (HF) that complicates it are the leading causes of death 
and disability in Europe and worldwide. The most effective 
treatment for limiting myocardial infarct (MI) size and 
preventing HF following AMI is timely myocardial reperfusion 
using primary percutaneous coronary intervention (PPCI). 
However, despite timely PPCI, mortality and morbidity 
following AMI remain significant, with 7% death and 22% 
hospitalization for HF at one year (Cung et al., 2015). 
Accordingly, new treatments are required to reduce MI size, 
in order to preserve left ventricular (LV) systolic function and 
prevent the development of post-AMI HF – a treatment strategy 
termed “cardioprotection.” 
After myocardial reperfusion, the most powerful intervention 
for reducing MI size in the experimental setting is ischemic 
conditioning, an endogenous cardioprotective phenomenon 
by which brief episodes of ischemia and reperfusion applied 
to the heart or a remote organ/tissue limit MI size (Hausenloy, 
2013;Hausenloy and Yellon, 2016;Hausenloy et al., 2017b). 
Intensive investigation of ischemic conditioning over 
the last 30 years (Hausenloy et al., 2016) has identified a 
large number of signaling pathways and therapeutic targets 
for cardioprotection (Hausenloy et al., 2013;Hausenloy et 
al., 2017a;Hausenloy et al., 2017b). However, despite this, 
no effective therapies for protecting the heart against acute 
ischemia/reperfusion injury (IRI) have been translated into 
the clinical setting for patient benefit. A large number of 
cardioprotective therapies have been investigated in AMI 
patients treated with PPCI including a growing number of high-
profile clinical studies, but the vast majority of these have failed 
to show benefit in terms of reducing MI size and improving 
clinical outcomes. 
The main challenge, therefore, is to improve the translation 
of novel cardioprotective therapies shown to be effective in the 
experimental setting into the clinical arena for patient benefit. 
Our EU-CARDIOPROTECTION COST Action (CA16225, 
4 years’ duration Oct 2017 to Sept 2021) will address this 
challenge by setting up a pan-European network of research 
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centers tasked with several key objectives, each of which will 
be addressed by four Working Groups (see Figure 1): (1) 
discovery of new therapeutic targets and innovative strategies 
for cardioprotection; (2) testing effects of combination therapy 
to target multiple signaling pathways both within and outside 
the cardiomyocyte; (3) investigating the effects of confounders 
(co-morbidities and co-medications) on cardioprotection; and 
(4) multi-center randomized controlled pre-clinical and clinical 
testing of novel cardioprotective therapies. 
The reasons for the failure to translate novel cardioprotective 
therapies into the clinical setting for patient benefit are multiple 
and complex and have been reviewed in a number of recent 
papers (Ovize et al., 2010;Hausenloy et al., 2013;Lecour et 
al., 2014;Ibanez et al., 2015;Perrino et al., 2017;Hausenloy 
et al., 2017b;Heusch, 2017). Here we focus on several 
of the most important factors and outline how our EU-
CARDIOPROTECTION COST Action will address these 
issues.
Therapeutic targets for cardioprotection: The majority of 
experimental studies have focused on targeting well-established 
signaling pathways and targets many of which have not 
proven to be beneficial in the clinical setting. Furthermore, the 
experimental approach has relied on a reductionist strategy 
focused on a single signaling pathway or target. As such, novel 
therapeutic targets and strategies need to be discovered in 
order to improve the translation of cardioprotection into the 
clinical setting, e.g. by taking into account unbiased “fishing” 
approaches by multi-omics technologies (Perrino et al., 2017). 
To address this, the aim of Working Group 1 (NEW 
TARGETS) of our EU-CARDIOPROTECTION COST Action 
will be to discover novel signaling pathways and therapeutic 
targets within and outside the cardiomyocyte, and identify 
innovative strategies for cardioprotection.
Single-targeted cardioprotective therapies: The majority 
of  experimental  s tudies have used a single-targeted 
approach, directed to one signaling pathway or target within 
cardiomyocytes. However, a large number of different 
cardioprotective pathways underlie ischemic conditioning. 
Furthermore, the detrimental effects of acute IRI on the 
heart are complex, interdependent, and involve a number of 
players outside of the cardiomyocyte such as the coronary 
microvasculature, inflammatory cells, red blood cells, platelets, 
and extracellular vesicles (Sluijter et al., 2018;Hausenloy et al., 
2017b;Heusch, 2016). 
As such, the aim of Working Group 2 (COMBINATION 
THERAPY) of our EU-CARDIOPROTECTION COST 
Action will be to investigate combination therapy directed to 
multiple cardioprotective pathways and targets both within 
and outside the cardiomyocyte as an innovative approach to 
cardioprotection.
Experimental models with low translational value: The 
majority of experimental studies have used healthy juvenile 
animal MI models, which do not adequately reflect the clinical 
setting, given that most ischemic heart disease patients 
are middle-aged, have co-morbidities (such as diabetes, 
hyperlipidemia, hypertension), and are on co-medications (such 
as anti-platelet therapies, statins, beta-blockers, angiotensin 
converting enzyme inhibitors, and/or anesthetics). There are 
also obvious species differences in cardioprotective signaling 
between rodents, larger mammals and humans. These factors 
have been shown to confound the efficacy of cardioprotective 
therapies, and should be taken into consideration when 
evaluating novel cardioprotective therapies in experimental and 
clinical settings (Ferdinandy et al., 2014). 
As such, the aim of Working Group 3 (CONFOUNDERS) 
of our EU-CARDIOPROTECTION COST Action will be to 
identify the key co-morbidities and co-medications which 
confound cardioprotection, in order to improve the translational 
value of the animal MI models. 
Therapies with inconsistent cardioprotective efficacy: Many 
of the cardioprotective therapies that have failed in the clinical 
setting did not show consistent and robust cardioprotection 
in the experimental setting. This can be attributed to 
methodological limitations of the pre-clinical studies including 
lack of randomization, non-blinded treatment allocation, 
non-blinded data analysis, lack of standardized animal AMI/
HF models and acute IRI protocols, and the lack of rigor in 
statistical methods. Therefore, more rigorous testing of novel 
cardioprotective therapies in the experimental setting are 
required to ensure that only the most promising therapies are 
investigated in the clinical arena. 
To  a d d r e s s  t h i s ,  t h e  a i m  o f  Wo r k i n g  G r o u p  4 
(CONSORTIUM) of our EU-CARDIOPROTECTION 
COST Action will be to set up a European Cardioprotection 
Consortium (ECC) for multi-center experimental testing of 
new cardioprotective therapies in clinically relevant small/large 
animals, and for testing new cardioprotective therapies in proof-
of-concept clinical studies in patients subjected to acute IRI 
including ST-segment elevation myocardial infarction (STEMI) 
and coronary artery bypass graft (CABG) patients.
Research Objectives of the COST Action
Working Group 1: New Targets
The majority of the experimental studies investigating novel 
cardioprotective therapies have focused on targeting well-
established signaling pathways/targets, many of which have not 
proven to be beneficial in the clinical setting. In some respects, 
this may have been because the therapy had not been optimized 
in terms of the experimental setting (dose, acute versus chronic 
administration and timing of therapy), and in this regard, 
there is an opportunity to optimize the treatment approach. In 
other cases, in which treatments have failed, novel therapeutic 
targets and strategies need to be discovered in order to improve 
the translation of cardioprotection from the laboratory to the 
clinical setting. These new cardioprotective strategies should 
focus on (a) discovering new therapeutic targets in novel 
cardioprotective pathways within the cardiomyocyte and (b) 
other components of acute IRI outside of the cardiomyocyte 
such as the microvasculature, inflammatory cells, and 
platelets. Potential novel targets for cardioprotection include i) 
inflammation targets such as macrophages/lymphocytes, RNA/
DNA, and inflammasome; ii) novel mechanisms of cell death 
such as necroptosis and pyroptosis; iii) extracellular matrix; iv) 
fibroblasts; v) endothelial cells and vascular smooth muscle; 
vi) platelets and vii) novel mitochondrial targets(Hausenloy et 
al., 2017b); and viii) novel insulin targets and zinc-transporters 
targets associated with sarcolemma, sarco(endo)plasmic 
reticulum and mitochondria in hyperglycemic, failing and aging 
heart (Tuncay et al., 2017;Tuncay et al., 2018;Olgar et al., 
2018).
The use of innovative strategies such as multi-omics 
(transcriptomics, epigenetics, proteomics, and metabolomics) 
and innovative in silico network biology evaluation is another 
objective of our COST Action in order to identify new 
therapeutic targets for cardioprotection. The pathophysiology 
of the ischemic heart is very complex; therefore, large-
scale, unbiased, global approaches capable of identifying 
multiple branches of the signaling networks activated in the 
ischemic/reperfused heart might be a preferred approach in the 
discovery of novel targets. Proteomics and metabolomics offer 
simultaneous readouts of hundreds of proteins and metabolites 
altered in the ischemic myocardium, and the possibility of 
integrating different -omics approaches gives new hope for a 
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better understanding of the complicated molecular signaling 
activated by acute myocardial ischemia and reperfusion (Perrino 
et al., 2017;Varga et al., 2015). In general, WG1 will contribute 
to an improved knowledge of the sequence of molecular events 
triggered by ischemia-reperfusion that ultimately lead to tissue 
damage. This is required for the development of novel and 
effective therapeutic approaches. The identification of novel 
therapeutic targets may lead to the design, synthesis, and testing 
of novel chemical modulators in both cells and animals.
Expected Research Outputs of WG1
1. To identify at least 6 novel targets for cardioprotection 
either within the cardiomyocyte (newly discovered signaling 
pathways)  or  outs ide the cardiomyocyte  ( involving 
inflammatory cells, fibroblasts, the microvasculature, red blood 
cells, or platelets).
2. To identify at least 3 innovative strategies for identifying 
novel targets for cardioprotection such as epigenetics or multi-
omics strategies (genomics, transcriptomics, metabolomics, 
lipidomics or proteomics).
Working Group 2: Combination Therapy
The majority of experimental studies have used a single-
targeted approach, directed to a single signaling pathway 
and target within the cardiomyocyte. However, there exists 
a number of different cardioprotective pathways underlie 
ischemic conditioning. Furthermore, the detrimental effects 
of acute IRI on the heart are complex, interdependent, and 
involve a number of players outside of the cardiomyocyte such 
as the microvasculature, extracellular matrix, inflammatory 
cells, red blood cells and platelets. For example, it has been 
shown that multiple cardioprotective interventions (each with 
a different mechanism of action), – e.g., mild hypothermia, 
sodium/hydrogen exchange blocker plus a P2Y12 inhibitor, 
– reduced MI size to a greater extent beyond the one that 
achieved by a P2Y12 inhibitor alone (Yang et al., 2013b;Yang 
et al., 2012;Yang et al., 2013a;Yang et al., 2013c). Here we 
will utilize the joint expertise of different European network 
members to investigate combination therapy directed to 
multiple cardioprotective pathways and targets both within and 
outside the cardiomyocyte as an innovative treatment strategy 
for cardioprotection. 
Expected Research Outputs of WG2
To identify at least 6 promising treatment strategies that 
are likely to have synergistic effects when administered 
in combination and that are directed to targets within the 
cardiomyocyte (newly discovered signaling pathways) or 
outside the cardiomyocyte (involving inflammatory cells, the 
extracellular matrix, the microvasculature, red blood cells, 
or platelets) for testing in pre-clinical acute myocardial IRI 
models.
Working Group 3: Confounders
Ischemic heart disease in humans is a complex disorder 
caused by, or associated with, cardiovascular risk factors and 
comorbidities, including hypertension, obesity, hyperlipidemia, 
diabetes, insulin resistance, heart failure, altered coronary 
circulation, and aging. These risk factors induce fundamental 
alterations in cellular signaling cascades that affect the 
development of IRI per se and responses to cardioprotective 
interventions. Moreover, some of the medications used to treat 
these risk factors, including statins, nitrates, and antidiabetic 
drugs, may impact cardioprotection by modifying cellular 
signaling (Ferdinandy et al., 2014). 
The majority of experimental studies have used healthy 
juvenile animal MI models, which are of low translational 
value since they do not adequately reflect the clinical 
setting given that most CVD patients are middle-aged, have 
multiple co-morbidities and are on a variety of different co-
medications. There are also obvious species differences in 
cardioprotective signaling between rodents, larger mammals, 
and humans. These factors have been shown to confound the 
efficacy of cardioprotective therapies and need to be taken into 
consideration when evaluating novel cardioprotective therapies 
in the experimental and clinical setting (Ferdinandy et al., 
2014). Therefore, in this WG, we will utilize the joint expertise 
of the European network members to investigate key co-
morbidities and co-medications that confound cardioprotection 
in order to improve the translational value of animal MI models.
Our aim will be to improve the pre-clinical evaluation of 
novel cardioprotective therapies identified in the experimental 
setting by investigating the effect of confounding factors such 
as co-morbidities (age, diabetes, hypertension, hyperlipidemia) 
and co-medications (anti-platelet agents, statins, beta blockers, 
anesthetics) on their cardioprotective efficacy. Importantly, the 
mechanisms through which these confounding factors interfere 
with cardioprotection elicited by ischemic conditioning are not 
clear and will also be investigated in this objective, as this will 
provide mechanistic insights into cardioprotection.
In order to achieve this goal, we will use more clinically 
relevant animal models that take into account co-morbidities 
and co-medications relevant to MI patients. Although 
studies have reported co-morbidities such as age, diabetes 
and left ventricular hypertrophy to attenuate the efficacy 
of cardioprotective therapies (Ferdinandy et al., 2014), the 
mechanisms underlying this effect are unknown and will be 
investigated in this objective. In addition, further studies are 
required to investigate the effect of co-medication such as anti-
platelet agents, statins, anesthetics and their impact on the 
efficacy of new cardioprotective therapies.
Expected Research Outputs of WG3
1. To identify at least the 2 most important co-morbidities 
to consider  when designing precl inical  and cl inical 
cardioprotection studies (factors include age, male sex, diabetes, 
hypertension, hypercholesterolemia).
2. To identify at least the 2 most important co-medications 
to consider  when designing precl inical  and cl inical 
cardioprotection studies (co-medications include anti-platelet 
agents, statins, anesthetics, nitrates).
Working Group 4: Consortium 
Many of the cardioprotective therapies that have failed 
in the clinical setting did not show consistent and robust 
cardioprotection in the experimental setting. This can be 
attributed to methodological limitations of the pre-clinical 
studies including lack of randomization, non-blinded treatment 
allocation, non-blinded data analysis, lack of standardized 
animal models and IRI protocols, and the lack of rigor in 
statistical methods. Therefore, more rigorous testing of novel 
cardioprotective therapies in the experimental setting is required 
to ensure that only the most promising therapies are investigated 
in the clinical arena. As such in this COST Action proposal, we 
will put in place a Consortium for (a) multi-center experimental 
testing of new cardioprotective therapies in clinically relevant 
small/large animal and human models of acute IRI; and (b) 
testing of new cardioprotective therapies in proof-of-concept 
clinical studies in patients subjected to acute IRI including 
STEMI and CABG patients.
The Consortium, which will be termed the European 
Cardioprotection Consortium (ECC), will allow multi-site 
testing of novel cardioprotective therapies in clinically relevant 
experimental small and large animal models and is, in part, 
modeled on the National Institute of Health-sponsored CAESAR 
collaborative network (Consortium for Preclinical Assessment 
of Cardioprotective Therapies) in the United States(Schwartz-
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Longacre et al., 2011;Lefer and Bolli, 2011;Jones et al., 2015). 
The ECC will improve upon the NIH CAESAR collaborative 
network by (a) building on the infrastructure and knowledge 
obtained from the 3 WGs, in identifying novel cardioprotective 
targets and innovative strategies; and (b) undertaking proof-of-
concept clinical studies in STEMI and CABG patients.
Expected Research Outputs of WG4
1. To put in place a network of research centers across Europe 
that will constitute the ECC for multi-center randomized 
control led pre-cl inical  and cl inical  test ing of  novel 
cardioprotective therapies.
2. To standardize acute myocardial IRI protocols across the 
consortium and select which small animal (mouse, rat, rabbit) 
and large animal (pig, dog) AMI/HF models to include in the 
ECC.
3. To identify at least 4 novel cardioprotective therapies from 
WG 1, 2, 3 and key confounders highlighted in WG3 for testing 
in our ECC.
4. To identify at least 2 novel cardioprotective therapies which 
have demonstrated consistent and robust cardioprotection in the 
ECC, for future testing in proof-of-concept clinical studies in 
STEMI and CABG patients.
Expected impact of the EU-CARDIOPROTECTION COST 
Action
The immediate impact of the current project will be to create 
a European network of research centers to discover and 
disseminate novel therapeutic targets and to define strategies 
for cardioprotection to treat patients with co-morbidities and 
on co-medications. This project will establish networks and 
relationships with research users. The EU-Cardioprotection 
project involves users at all stages of research, including working 
with user stakeholder and participatory groups. The short-term 
impact will be achieved by exchanging ideas, knowledge, tools, 
and data of scientists working on different but related systems 
using various approaches.
The short-term scientific, technological and socio-
economic impacts will provide: i) The knowledge basis for 
research scientists at all levels and industrial players to increase 
the number of successful innovative development projects 
aimed at discovering novel cardioprotective therapies. The 
COST Action will provide state-of-the-art, detailed protocols for 
measuring MI size in mice, rabbits, and pigs in a manner that 
is rigorous, accurate, and reproducible, thereby helping to best 
inform which therapies should be taken forward by industrial 
partners for further development and commercialization. ii) The 
capability of the COST Action members to jointly apply for a 
Horizon 2020 grant to set up the European Cardioprotection 
Collaboration network of research centers for the pre-clinical 
and clinical testing of novel cardioprotective therapies as 
outlined in WG4 of the project. iii) The ability to validate the 
efficacy and safety of current cardioprotective strategies such 
as ischemic postconditioning and remote ischemic conditioning 
in the treatment of AMI in the real world, i.e. in patients with 
major co-morbidities and co-medications. v) Data for early 
exclusion of candidate strategies unlikely to succeed in AMI 
patients.
The long-term scientific, technological and socio-
economic impacts include: i) accumulation of the critical 
mass to understand problems with high levels of complexity 
such as cardioprotection -- problems that can only be solved 
by a concerted effort of multidisciplinary teams; ii) enabling 
researchers from less research intensive countries to interact 
and share ideas, resources and personnel with scientists 
from countries in which research enjoys a high priority iii) 
creation of new, and strengthening of existing, interactions 
among European scientists and international experts via our 
external advisory board; iv) setting up the ECC network of 
research centers for pre-clinical and clinical testing of novel 
cardioprotective therapies, which will lead to successful 
development of cardioprotective therapies, thereby solving an 
unmet need in the treatment of ischemic heart disease, which 
is currently the leading cause of morbidity and mortality in the 
EU; v) increasing the number and success rate of innovative 
development projects, creation of new jobs and increased 
competitiveness of innovative small-to-medium enterprises 
(SMEs); vi) heightening the impact of cardioprotection research 
on policy makers, regulatory bodies and national decision 
makers as well as on the private sector; vii) developing novel 
technologies and services that will impact on the growth of 
the EU’s knowledge-driven economy; and viii) contributing to 
healthy aging in the European population and providing a major 
impact on quality of life.
COST Action research network activities 
The following Network Activities listed below will be used in 
our EU-CARDIOPROTECTION COST Action to deliver the 
main research objectives of our 4 WGs (see Figure 1).
WG Meetings: Bi-annual WG Meetings will allow the COST 
partners and others to disseminate and share knowledge 
relevant to the objectives of the 4 different, but closely inter-
related, WGs. Invited speakers and chairs will be considered 
with respect to gender balance and geographical distribution. 
Early career investigators (ECIs) will be encouraged to chair 
sessions and present at the WG Meetings. We will invite leading 
international experts in preclinical and clinical cardioprotection 
to attend the meeting and provide expert input and advice to 
the relevant WGs. We will also invite international researchers 
who have expertise in setting up a similar cardioprotection 
research consortium in the U.S. – the NIH CAESAR Network 
-- to provide advice on setting up our ECC in WG4. Our first 
WG Meeting took place in October 2017 in Brussels at the 
COST Headquarters, and outlined the main objectives and 
activities of our EU-CARDIOPROTECTION Cost Actions. 
Our next WG meeting, which will be held in the Medical 
University of Vienna, Austria, in March 2018 (local organizers, 
Bruno Podesser and Mariann Gyöngyösi), will begin the 
implementation of strategies to achieve the WG objectives of 
the COST Action.
Figure 1. Overview of the EU-CARDIOPROTECTION COST Action 
CA16225 organization and activities. The COST Action Core Group 
will oversee the EU-CARDIOPROTECTION COST Action Program (4 
years’ duration, Oct 2017 to Sept 2021) in conjunction with the COST 
Action Management Committee (MC). The COST Action will utilize the 
COST Action Networking Activities to achieve the research objectives 
of the four Working Groups (WGs). 
Conditioning Medicine 2018 | www.conditionmed.org121
Conditioning Medicine | 2018, 1(3):116-123REVIEW ARTICLE
Training schools: In order to support the training and 
development of ECIs, training schools will be organized 
on a variety of topics relevant to cardioprotection research 
including (1) novel methods for discovering novel targets for 
cardioprotection and innovative cardioprotective strategies such 
as multi-omics approaches; (2) the use of combination therapies 
as a multi-targeted approach to cardioprotection; (3) clinically 
relevant animal AMI/HF based on co-morbidities (age, diabetes, 
hypercholesterolemia) and consideration of relevant co-
medications (statins, nitrates, anesthetics, anti-platelet agents); 
and (4) guidelines for undertaking multicenter experimental 
studies and proof-of-concept clinical studies.
Short-term Scientific Missions (STSMs): In order to achieve 
long-lasting effects of this COST Action, ECIs will be supported 
in their networking activities by STSMs (duration of one week 
to 3 months and supported by a fixed grant from the COST 
Action). These will allow ECIs to learn new research techniques 
and gain valuable knowledge and experience from an institution 
or laboratory in another COST country. Increasing collaboration 
is important to make Europe more competitive. Exchanging 
ideas and knowledge across borders will lead to more successful 
projects. So far our EU-CARDIOPROTECTION COST Action 
has initiated 4 STSMs involving COST Member Countries 
and International Partner Countries (UK-Singapore, Greece-
Germany, Slovakia-Hungary, Romania-Austria). We intend 
to initiate a further 8 STSMs each year for the duration of the 
COST Action.
Dissemination activities: A website providing access to the 
generated knowledge and annual newsletters, with mutual 
links to websites relevant to this COST Action has been 
set up at www.cardioprotection.eu. Scientific publications 
disseminating knowledge of the WG will be published as 
original articles, reviews and position papers in conjunction 
with other cardiovascular organizations and societies. Our 
COST Action will also sponsor joint scientific sessions at other 
European and international cardiovascular meetings including 
the International Society of Heart Research-European Section 
(ISHR-ES) meetings and ESC Working Group on Cellular 
Biology of the Heart.  
Conference Grants: This will enable PhD students and ECIs 
from participating Inclusiveness Target Countries to attend 
international cardiovascular conferences that are not organized 
by our COST Action.
Summary of the EU-CARDIOPROTECTION COST Action
In summary, our COST Action will put in place a pan-European 
Research Network of leading experts in cardioprotection to 
jointly develop new initiatives and new strategies for finding 
innovative and more effective approaches to cardioprotection 
and for optimizing the pre-clinical and clinical evaluation 
of new cardioprotective therapies, so as to improve their 
translation into the clinical setting for patient benefit. The COST 
Action will co-ordinate and strengthen European research in 
the field of cardioprotection and accelerate scientific progress 
through the dissemination and sharing of new therapeutic 
targets among network members and industrial partners, thereby 
facilitating the discovery of new cardioprotective therapies. 
By utilizing the joint expertise of different European network 
members, we will investigate factors that confound the efficacy 
of new cardioprotective therapies, including comorbidities (such 
as age, diabetes, and hypertension) and co-medications (such 
as anti-platelet therapies, statins and beta-blockers). Finally, we 
will set up a European network of research centers for multi-
center laboratory testing of new cardioprotective therapies using 
small and large animal models of acute IRI in order to select 
those therapies most likely to succeed in the clinical setting. All 
aspects of this COST Action proposal require a critical mass of 
partners covering a wide geographic distribution across Europe 
in order to deliver the objectives outlined in this proposal and 
improve clinical outcomes for AMI patients in Europe and 
worldwide.
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